New Generation Drug Development Pipeline from In-silico Identification to Preclinical Evaluation for Novel Drug Candidates in Glioblastoma
CSEF · 2023 Mammalian Biology First Award
Overview
Glioblastoma(GBM) is the most common malignancy of the central nervous system in adults. Despite medical advancements, the continued shortfall of many treatments such as Temozolomide, alongside the stagnant survival rate improvements (<13%) have led to pressing concerns for novel drug discovery methodologies. This study developed and utilized two key stages within the drug discovery process, namely: drug-target prediction and in-vitro preclinical functional evaluation to identify a safe, bioactive, and effective treatment for GBM. Furthermore, preliminary analysis on mechanisms of cell proliferation were conducted on GBM in order to identify a druggable target. Stage 1 fabricated a novel five phase in-silico pipeline for drug-target prediction against Ephrin-Type-A Receptor 2. 1562 FDA approved drugs were run against the developed pipeline and analyzed for bond type, location, repulsion, Gibbs free energy, stability, interactions over time, blood brain barrier permeability, and possible false positives (PAINS). These results provided five plausible hits: Empagliflozin, Mycophenolate mofetil, Canagliflozin, Rivaroxaban, and Carvedilol. Stage 2 involved the preclinical evaluation of the top five predicted drug candidates using an in-vitro Suphorhodamine-B cytotoxicity assay on glioblastoma cell lines U251 and SF295. Canaglifozin and Empagliflozin exhibited promising results with IC50 values around 40 μM. Mycophenolate mofetil (IC50: 5μM) and Carvedilol (IC50:16μM) showcased highly promising results, a major improvement from serendipity approaches. Mycophenolate mofetil and Carvedilol results warranted further testing in pancreatic cell line SUIT-2 due to similar mechanisms of cancer progression. SUIT-2 results paralleled effectiveness noticed in GBM affirming testing within clinical trials.
Source coverage
This record comes from a published award list, not a complete project archive. Its abstract comes from CSEF's public project showcase as archived by the Internet Archive before judging (https://web.archive.org/web/20230401224130/https://ca-csef.zfairs.com/showcase/ShowcaseInfo?f=838e60b7-ea75-46e8-865c-fde4864244b3); the version presented may differ.
Awards (1)
Competition history
- CSEF 2023
Resources
Related projects
ISEF · 2023
New Generation Drug Development Pipeline From in silico Identification to Preclinical Evaluation for Novel Drug Candidates in Glioblastoma
AJAS · 2025
In Vitro Approach to Identify Preclinical Drug Targets to Treat Glioblastoma Multiforme
ISEF · 2026
EZ-CDD: Computational Drug Discovery and Design of EZH2 Inhibitors for Glioblastoma Multiforme Large-Scale Virtual Screening, Rational Optimization, Fragment-Based Design
ISEF · 2026
Computational Identification of Novel Endocan Inhibitors for Targeted Glioblastoma Therapy Through Molecular Docking and ADMET Analysis
ISEF · 2021
Network Biology Methods for Improved Drug Discovery in Brain Cancers
AJAS · 2020
Targeting the Nf-Kb and Mgmt Pathways in Newly Diagnosed Glioblastoma
AJAS · 2026
Computational Design of Novel CD117-Specific RNA Aptamers for GBM Therapy
CWSF · 2026
Brain-Penetrating Bioconjugate M13-CTX-PEP-1 for Targeted Glioblastoma Therapy In Silico
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: California Science & Engineering Fair public projects